Effect of metformin and simvastatin in treatment of polycystic ovarian syndrome

Comparison of metabolic, endocrine, and clinical outcomes of treatment with simvastatin and metformin in women with polycystic ovaries

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140525017827N8

Enrollment

144

Registered

2020-04-10

Start date

2020-04-13

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: receive 20 mg of simvastatin every night after dinner. Intervention 2: Intervention group: receive 500 mg of metformin three times daily after meals.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: oligomenorrhea or amenorrhea clinical or laboratory findings of hyperandrogenism existence of polycystic ovaries in ultrasound examination) will be invited to take part in the study Aging 18-40 years single Not suffering from thyroid disorder, Cushing’s syndrome, and hyperprolactinemia Not having kidney disorder, liver disorder, diabetes, and lipid profile disorder Not having the history of cardiovascular diseases and hypertension Not having used ovarian function stimulators or hormonal drugs during the past 3 months Not having used medications affecting insulin or lipid profiles within the past 3 months Not smoking Not consuming alcohol Not using drugs Not suffering from breast cancer Not having medical contraindications Not having maladaptation

Exclusion criteria

Exclusion criteria: Getting married Not being willing to continue treatment Presentation of side effects due to consumption of study medications Not following the research protocol Losing weight by 3 kg or more within the past 2 months

Design outcomes

Primary

Measure	Time frame
Endocrine parameters (total testosterone, free testosterone, DHEA, estradiol, FSH, LH, SHBG, prolactin, and TSH). Timepoint: before and after intervention. Method of measurement: Eliza Kit.;Metabolic parameters (bilirubin, aminotransferases, total cholesterol, LDL, HDL, TG, fasting glucose, 2-hour glucose tolerance test, fasting insulin, insulin sensitivity index, hs-CRP, sVCAM, and homocysteine). Timepoint: Before and after intervention. Method of measurement: Eliza Kit.	—

Measure

Time frame

Endocrine parameters (total testosterone, free testosterone, DHEA, estradiol, FSH, LH, SHBG, prolactin, and TSH). Timepoint: before and after intervention. Method of measurement: Eliza Kit.;Metabolic parameters (bilirubin, aminotransferases, total cholesterol, LDL, HDL, TG, fasting glucose, 2-hour glucose tolerance test, fasting insulin, insulin sensitivity index, hs-CRP, sVCAM, and homocysteine). Timepoint: Before and after intervention. Method of measurement: Eliza Kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaliehe Kamali

Shiraz University of Medical Sciences

malihe_kamali@yahoo.com+98 71 3612 8258

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026